Viral resistance in HCV infection.

Antonio Craxi, Valeria Cento, Carlo Federico Perno, Velia Chiara Di Maio, Francesca Ceccherini-Silberstein, Francesca Ceccherini-Silberstein, Francesca Ceccherini-Silberstein, Antonio Craxì

Risultato della ricerca: Articlepeer review

4 Citazioni (Scopus)


The introduction of new multi-genotypic direct acting antivirals(DAA) in clinical practice has revolutionized HCV treatment,permitting the achievement of >95% rates of sustainedvirological response in many patients. However, virologicalfailures can occur particularly if the treatments are sub optimaland/or with too short duration. Failure is often associated withdevelopment of resistance. The wide genetic variability in termsof different genotypes and subtypes, together with the naturalpresence and/or easy development of resistance duringtreatment, are intrinsic characteristics of HCV that may affectthe treatment outcome and the chances of achieving avirological cure. This review explores in detail the aspects ofHCV innate and treatment-induced resistance to newinterferon-free DAA regimens.
Lingua originaleEnglish
pagine (da-a)115-127
Numero di pagine13
RivistaCurrent Opinion in Virology
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2400.2406???


Entra nei temi di ricerca di 'Viral resistance in HCV infection.'. Insieme formano una fingerprint unica.

Cita questo